Showing 221-230 of 747 results for "".
Dupilumab For the Management of Pembrolizumab-induced Rash: A Case Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/dupilumab-for-the-management-of-pembrolizumab-induced-rash-a-case-report/23841/Is Irritable Bowel Linked to Irritable Skin?
https://practicaldermatology.com/columns/clinical-focus-1/is-irritable-bowel-linked-to-irritable-skin/23324/Exploring irritable bowel syndrome’s link to dermatologic conditions.How Epidermolysis Bullosa Treatments Went from Blisters to Breakthroughs
https://practicaldermatology.com/topics/rare-disease/how-epidermolysis-bullosa-treatments-went-from-blisters-to-breakthroughs/54391/Current FDA-approved therapies oleogel-S10, beremagene geperpavec, and prademagene zamikeracel represent major therapeutic breakthroughs for the treatment of epidermolysis bullosa (EB). Earlier systemic intervention, improved nutrition, and proactive management of complications have extended survivDermWireTV: AAD VMX Highlights, Upneeq Launches for Ptosis
https://practicaldermatology.com/topics/practice-management/dermwiretv-aad-vmx-highlights-upneeq-launches-for-ptosis/19931/The American Academy of Dermatology's VMX format delivers updates on a range of hot topics in dermatology, including an update on the COVID-19 dermatology vaccine registry from Esther Freeman, MD and teledermatology from Jules Lipoff, MD. Upneeq, a newly launched oxymetazoline eyedrop from RVL pharmPregnancy and Melanoma: What We Know About the Risks
https://practicaldermatology.com/topics/practice-management/pregnancy-and-melanoma-what-we-know-about-the-risks/21041/Against a backdrop of conflicting findings, a new study suggests a significant risk associated with melanoma during pregnancy.Hidradenitis Suppurativa: Seeking More Pieces to the Puzzle
https://practicaldermatology.com/topics/rare-disease/hidradenitis-suppurativa-seeking-more-pieces-to-the-puzzle/23669/Evidence suggests that integrated approaches to care may yield best results for many patients.Revisiting Cyclosporine in the Age of Biologics: Update on Efficacy and Mechanism of Action
https://practicaldermatology.com/topics/general-topics/revisiting-cyclosporine-in-the-age-of-biologics-update-on-efficacy-and-mechanism-of-action/21937/Increased understanding of the immunologic basis of psoriasis supports the role of cyclosporine in patient management.The Role of Inflammation in Acne Vulgaris
https://practicaldermatology.com/topics/general-topics/the-role-of-inflammation-in-acne-vulgaris/21512/Multiple lines of evidence support a pivotal role for inflammation in the pathogenesis of acne vulgaris.Update on Diagnosis and Topical Management of Erythrasma
https://practicaldermatology.com/topics/general-topics/PD0909_03-php/22767/This under-diagnosed cutaneous infection is caused by a bacterium but may respond to anti-fungal therapies.Monitoring Biologic Therapy In Psoriasis: A Primer
https://practicaldermatology.com/topics/psoriasis/monitoring-biologic-therapy-in-psoriasis-a-primer/20931/Treatments are generally safe and well-tolerated, however, prescribers must monitor for risk factors.